TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02539342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caphosol
Description: Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day as follows:~* Each dose consists of two 15 mL syringes, to be mixed at time of administration. Caphosol must be used within 15 minutes of mixing.~  o Participants may increase the use to 6 times per day if you have symptoms of mucositis.~* Using one of the syringes, rinse and gargle (if patient is able) for one minute and then spit. Repeat using the remaining syringe.~  * For younger patients (less than or equal to 6 years of age), volume may be reduced to two syringes containing 5-10 mL each.~ * For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Repeat using the second syringe.~* Patients are to avoid other oral medications, other mouth cares and food or drink for 15 minutes after using Caphosol.~* Patients may use Biotene (5-10 mL) to swish and spit after the 15 minutes has passed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biotene
Description: • Use 5 to 10 mL of Biotene to swish and spit~o For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Prior to swabbing the patient's mouth, pour Biotene into a cup and using the medical sponge, soak up the solution and use the swab to coat the inside of the patient's mouth. Repeat with a second swab.
Study: NCT02566031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol and glycopyrronium (QVA149)
Description: Capsules for inhalation delivered via SDDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Capsules for inhalation delivered via HandiHaler® device
Study: NCT00043420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3512676
Description: Weekly subcutaneous injections of 0.08mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3512676
Description: Weekly subcutaneous injections of 0.16mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3512676
Description: Weekly subcutaneous injections of 0.24mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3512676
Description: Weekly subcutaneous injections of 0.28mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3512676
Description: Weekly subcutaneous injections of 0.32mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3512676
Description: Weekly subcutaneous injections of 0.36mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3512676
Description: Weekly subcutaneous injections of 10 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-3512676
Description: Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
Study: NCT01920230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-ACT-intervention
Description: Half of the participants (n=109) is assigned to intervention group. The intervention is based on Mindfulness-program presented by Williams \& Penman (2011) and on principles of acceptance-commitment therapy (ACT). It aims to increase mindfulness skills and psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings as well as support clarifying individual values and value-based actions. The basic principles are presented in weekly small group meetings. Participants are guided to deepen their experiences through exercises and information that is provided via specific web-site.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Half of the participants (n=109) don't get any special treatment. However the present study explores what kind of support they have had during the program.
Study: NCT03832010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crisaborole
Description: Participants will be instructed to apply crisaborole to affected areas with eczema.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Hydrocortisone Ointment
Description: Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Ointment
Description: Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone Ointment
Description: Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Triamcinolone ointment
Description: Participants will be instructed to apply triamcinolone to affected areas on the body excluding face, armpits or groin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone ointment
Description: Participants will be instructed to apply triamcinolone to affected areas on the body excluding face, armpits or groin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triamcinolone ointment
Description: Participants will be instructed to apply triamcinolone to affected areas on the body excluding face, armpits or groin.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Aquaphor
Description: Participants will be instructed to moisturize all over the body with Aquaphor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aquaphor
Description: Participants will be instructed to moisturize all over the body with Aquaphor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aquaphor
Description: Participants will be instructed to moisturize all over the body with Aquaphor.
Study: NCT01280487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSTK474
Description: Daily oral dosing for 21 days each cycle
Study: NCT04333394

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The probiotic capsules will be administrated once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with probiotic supplementation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules will be administered once a day. medication with Ritalin starts at the onset of the study in a dose-dependent manner and simultaneous with placebo supplementation.
Study: NCT01603576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype wide view suprachoroidal retinal prosthesis
Description: Manufacturer = Bionics Institute, Australia
Study: NCT02277106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02766751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIVPASS
Description: The 7-session HIVPASS intervention is provided to individuals randomized to the HIVPASS study arm.
Study: NCT04609579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab (KEYTRUDA®) will be administered as an intravenous infusion on Day 8 in Cycle 1 (28-day cycle) and on Day 1 of each 21-day cycle thereafter for up to 6 cycles, or until disease progression or unacceptable toxicity occurs.
Study: NCT02766751

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: The 7-sessions of Health Education is provided to individuals randomized to the Health Education study arm.
Study: NCT00990158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phytonadione (Vitamin K1)
Description: A daily dose of 150 micrograms of vitamin K medication given orally for a total of 7 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A daily dose of matching placebo medication given orally for a total of 7 months
Study: NCT04566029

Intervention type: BIOLOGICAL
Intervention: Blood test
Description: The patients' blood will be collected in four 5mL heparinized tubes

Intervention type: BIOLOGICAL
Intervention: Blood test
Description: The patients' blood will be collected in four 5mL heparinized tubes

Intervention type: BIOLOGICAL
Intervention: Stool sample
Description: The patients' stools will be collected at home
Study: NCT05486195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDI-118
Description: SDI-118 Powder in Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDI-118
Description: SDI-118 Powder in Capsule
Study: NCT04566029

Intervention type: BIOLOGICAL
Intervention: Stool sample
Description: The patients' stools will be collected at home
Study: NCT00214162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Health Enhancement Support System
Description: Full CHESS

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: computer with internet
Description: computer with internet use x 1 year
Study: NCT00310050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: 500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).
Study: NCT04566029

Intervention type: OTHER
Intervention: Questionnaires
Description: At each visit, the following questionnaires will be collected: QLQ-C30 and EQ5D-5L Appendix 16.2 and PRO CTCAE

Intervention type: OTHER
Intervention: Questionnaires
Description: At each visit, the following questionnaires will be collected: QLQ-C30 and EQ5D-5L Appendix 16.2 and PRO CTCAE
Study: NCT03108924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.

Intervention type: DRUG
Group type: OTHER
Intervention: Gefapixant
Description: After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.
Study: NCT02943109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Touch
Description: Participants receives an in person visit from an technology navigator who helps to explain the technology to the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Touch
Description: Participants receives an in person visit from an technology navigator who helps to explain the technology to the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Touch
Description: Participants receives a visit from a patient navigator who helps to explain how to navigate the hospital system (active control).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Touch
Description: Participants receives a visit from a patient navigator who helps to explain how to navigate the hospital system (active control).
Study: NCT03108924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.
Study: NCT01848873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: amlodipine 5mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine-FA tablet, low dose group
Description: 5mg amlodipine combined with 0.4 mg of folic acid, daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine-FA tablet ,high dose group
Description: amlodipine 5mg and folic acid 0.8mg daily
Study: NCT01343407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1029 10 mg
Description: Six capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1029 100 mg
Description: Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-1029 10 mg
Description: Six capsules once daily for 5 days in Period 1, and the same in Period 2, 3, or 4 in a crossover design.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MK-1029 10 mg
Description: Six capsules once daily for 5 days in Period 1, and the same in Period 2, 3, or 4 in a crossover design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-1029 100 mg
Description: Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MK-1029 100 mg
Description: Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
Study: NCT00517491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide (Autogel formulation)
Description: 120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study.
Study: NCT00784810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone
Description: 5/2.5, 10/5 and 20/10 mg oxycodone/naloxone combination, 12 hourly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine/Paracetamol
Description: 15/500 and 30/500 mg codeine/paracetamol tablets, 2 tablets 6 hourly
Study: NCT01546896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buspirone+alprazolam
Description: day 1\~7: buspirone 10mg/d + alprazolam 0.5mg / day 8\~28: buspirone 20mg/d + alprazolam 0.5mg / day 29\~56: buspirone 20\~30mg/d + alprazolam 0.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam
Description: 0.5mg/d
Study: NCT00249535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Rewards (prizes) for abstinence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Rewards (prizes) for abstinence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Rewards (prizes) for abstinence
Study: NCT03568318

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets taken orally once a day
Study: NCT05486195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDI-118
Description: SDI-118 Powder in Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDI-118
Description: SDI-118 Powder in Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDI-118
Description: SDI-118 Powder in Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT01846338

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: green tea extract EGCG
Description: EGCG, 500mg, tid, 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extract EGCG
Description: EGCG, 500mg, tid, 4 weeks
Study: NCT03953092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: YG1699 at Multiple Doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: YG1699 at Multiple Doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: YG1699 at Multiple Doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: YG1699 at Multiple Doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: YG1699 at Multiple Doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: YG1699 at Multiple Doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: YG1699 at Multiple Doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: YG1699 at Multiple Doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos
Study: NCT02268552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: branaplam
Study: NCT00615043

Intervention type: PROCEDURE
Intervention: Bladder biopsy
Description: provision of bladder tissue via cystoscopic biopsy during planned TURBT
Study: NCT01938755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Description: levobupivacaine plus 60 mg dextrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Description: levobupivacaine plus 80 mg dextrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Description: levobupivacaine plus 100 mg dextrose
Study: NCT03637946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Device: SHOFU beautifil II LS
Description: Restorative system FL-Bond II (self-etching adhesive system)/ beautifil II (composite restorative) were used following manufacturer's instructions
Study: NCT02211716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeGraft Peripheral Stent Graft System
Study: NCT05475054

Intervention type: PROCEDURE
Intervention: Minimally invasive liver resection
Description: A liver resection performed by minimally invasive (keyhole) surgery
Study: NCT00944138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation methods
Description: Relaxation methods will include mindful meditation techniques for the intervention and listening to music for the control arm
Study: NCT02943109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Tech
Description: Patient receives full-suite access to an inpatient patient portal with bi-directional communication enabled.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Tech
Description: Patient receives full-suite access to an inpatient patient portal with bi-directional communication enabled.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Tech
Description: Patient receives a limited access version of the inpatient patient portal with bi-directional communication disabled.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Tech
Description: Patient receives a limited access version of the inpatient patient portal with bi-directional communication disabled.
Study: NCT03048058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brimonidine topical gel 0.33% & survey
Description: The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brimonidine topical gel 0.33% & SOC
Description: All subjects will receive standard-of-care brimonidine topical gel 0.33%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brimonidine topical gel 0.33% & SOC
Description: All subjects will receive standard-of-care brimonidine topical gel 0.33%
Study: NCT02526199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Sciatic nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Sciatic nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Adjuvant to perinerual block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Adjuvant to perinerual block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Adjuvant to perinerual block
Study: NCT02625922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Description: Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Description: Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen
Study: NCT00031629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given IV
Study: NCT03710837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: Two different lectures covering essential clinical skills but one designed to explore the hypothesis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red flag education
Description: Two different lectures covering essential clinical skills but one designed to explore the hypothesis